<DOC>
	<DOCNO>NCT00189631</DOCNO>
	<brief_summary>To compare maintenance therapy observation metastatic breast cancer patient respond ( stabilize ) 1st-line chemotherapy . Main endpoint disease-free survival . Secondary endpoint overall survival tolerance . A total 200 patient include .</brief_summary>
	<brief_title>UFT/LV Maintenance Vs Observation Metastatic Breast Cancer Responsive Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>metastatic breast cancer objective response stabilisation 6 8 cycle first line chemotherapy time period end chemotherapy randomization &lt; 4 week age 18 year Performance status ( OMS ) &lt; 2 . Life expectancy &gt; 3 month Biological criterion randomization : Neutrophiles &gt; 1.5 x 109 G/L ; Pl . &gt; 100 x 109 G/L ; Hb &gt; 10 g/dl ; Creatininemia &lt; 1,5 UNL ; Bili . &lt; 2 UNL ; Transaminases &lt; 2,5 UNL ; Alcalines Phosphatases &lt; 2,5 UNL Signed write informed consent Metastatic breast cancer receive one chemotherapy line . Tumor progression chemotherapy Free interval primary tumor metastasis &gt; 5 year , estrogen receptor without visceral metastasis Free interval primary tumor metastasis &lt; 18 month adjuvant chemotherapy first lime chemotherapy lead tumor stabilization Concomitant hormonotherapy Other cancer Symptomatic brain metastases Any uncontrolled severe disease except breast cancer ( especially cardiac failure LVEF &lt; 50 % coronary insufficiency Psychiatric disorder Other concomitant trial Male patient Pregnancy breastfeeding ( effective contraception mandatory case woman childbearing potential ) History high dose chemotherapy bone marrow transplantation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>